Literature DB >> 15209455

Functional status and muscle strength in people with Duchenne muscular dystrophy living in the community.

Ken Uchikawa1, Meigen Liu, Kozo Hanayama, Tetsuya Tsuji, Toshiyuki Fujiwara, Naoichi Chino.   

Abstract

OBJECTIVE: To describe activity limitation of people with Duchenne muscular dystrophy who are living in the community and to correlate it with age and muscle strength.
DESIGN: Descriptive, correlational.
SUBJECTS: Twenty-seven children with Duchenne muscular dystrophy aged 7-14 years who are living in the community.
METHODS: The subjects' activity limitation was evaluated using the Functional Independence Measure and the muscle strength of their major upper and lower limb muscles was evaluated with manual muscle testing. The Functional Independence Measure was correlated with age and manual muscle testing, and the pattern of activities of daily living limitations and factors related to it were analysed.
RESULTS: There were significant correlations between age and averaged MMT score (Spearman's rho = -0.63, p < 0.01), age and Functional Independence Measure motor score (rho = -0.52, p < 0.01), and Functional Independence Measure motor score and averaged manual muscle testing (rho = 0.77, p < 0.01). At similar manual muscle testing level, children with good cognitive function (Functional Independence Measure cognitive score > or = 26) showed significantly higher Functional Independence Measure motor scores than those with poor cognitive function (Mann-Whitney U test, p < 0.01). For individual Functional Independence Measure items, eating and bowel management were the easier, whereas transfer and stair climbing were the more difficult. Patients with mean muscle strength > or = grade 3 were rated as relatively independent, while those with a mean muscle strength < grade 3 were rated as maximal or total assistance (Mann-Whitney U test, p < 0.05).
CONCLUSION: Activities of daily living in patients with Duchenne muscular dystrophy are related to age and muscle strength, and manual muscle testing grade 3 is an important cut-off point to predict their disability.

Entities:  

Mesh:

Year:  2004        PMID: 15209455     DOI: 10.1080/16501970410023461

Source DB:  PubMed          Journal:  J Rehabil Med        ISSN: 1650-1977            Impact factor:   2.912


  10 in total

1.  Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy.

Authors:  Sunita Mathur; Donovan J Lott; Claudia Senesac; Sean A Germain; Ravneet S Vohra; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

2.  Decreased gray matter concentration and local synchronization of spontaneous activity in the motor cortex in Duchenne muscular dystrophy.

Authors:  S-Y Lv; Q-H Zou; J-L Cui; N Zhao; J Hu; X-Y Long; Y-C Sun; J He; C-Z Zhu; Y He; Y-F Zang
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-29       Impact factor: 3.825

3.  Genitourinary health in a population-based cohort of males with Duchenne and Becker Muscular dystrophies.

Authors:  Yong Zhu; Paul A Romitti; Kristin M Caspers Conway; Sunkyung Kim; Ying Zhang; Michele Yang; Katherine D Mathews
Journal:  Muscle Nerve       Date:  2015-06-03       Impact factor: 3.217

4.  Shoulder strength profiles in children with and without brachial PLEXUS PALSY.

Authors:  Sylvain Brochard; Katharine Alter; Diane Damiano
Journal:  Muscle Nerve       Date:  2014-05-09       Impact factor: 3.217

5.  Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.

Authors:  Todd Levine
Journal:  Drug Des Devel Ther       Date:  2012-06-11       Impact factor: 4.162

6.  Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Authors:  Katharine Bushby; Richard Finkel; Brenda Wong; Richard Barohn; Craig Campbell; Giacomo P Comi; Anne M Connolly; John W Day; Kevin M Flanigan; Nathalie Goemans; Kristi J Jones; Eugenio Mercuri; Ros Quinlivan; James B Renfroe; Barry Russman; Monique M Ryan; Mar Tulinius; Thomas Voit; Steven A Moore; H Lee Sweeney; Richard T Abresch; Kim L Coleman; Michelle Eagle; Julaine Florence; Eduard Gappmaier; Allan M Glanzman; Erik Henricson; Jay Barth; Gary L Elfring; Allen Reha; Robert J Spiegel; Michael W O'donnell; Stuart W Peltz; Craig M Mcdonald
Journal:  Muscle Nerve       Date:  2014-10       Impact factor: 3.217

7.  Extensive Functional Evaluations to Monitor Aerobic Training in Becker Muscular Dystrophy: A Case Report.

Authors:  Caterina Tramonti; Bruno Rossi; Carmelo Chisari
Journal:  Eur J Transl Myol       Date:  2016-06-13

8.  Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial.

Authors:  Clementina Sitzia; Mirella Meregalli; Marzia Belicchi; Andrea Farini; Maddalena Arosio; Denise Bestetti; Chiara Villa; Luca Valenti; Paolo Brambilla; Yvan Torrente
Journal:  Front Neurol       Date:  2019-07-23       Impact factor: 4.003

9.  Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001).

Authors:  Takashi Nakajima; Yoshiyuki Sankai; Shinjiro Takata; Yoko Kobayashi; Yoshihito Ando; Masanori Nakagawa; Toshio Saito; Kayoko Saito; Chiho Ishida; Akira Tamaoka; Takako Saotome; Tetsuo Ikai; Hisako Endo; Kazuhiro Ishii; Mitsuya Morita; Takashi Maeno; Kiyonobu Komai; Tetsuhiko Ikeda; Yuka Ishikawa; Shinichiro Maeshima; Masashi Aoki; Michiya Ito; Tatsuya Mima; Toshihiko Miura; Jun Matsuda; Yumiko Kawaguchi; Tomohiro Hayashi; Masahiro Shingu; Hiroaki Kawamoto
Journal:  Orphanet J Rare Dis       Date:  2021-07-07       Impact factor: 4.123

10.  Improvements in motor tasks through the use of smartphone technology for individuals with Duchenne muscular dystrophy.

Authors:  Camila Miliani Capelini; Talita Dias da Silva; James Tonks; Suzanna Watson; Mayra Priscila Boscolo Alvarez; Lilian Del Ciello de Menezes; Francis Meire Favero; Fátima Aparecida Caromano; Thais Massetti; Carlos Bandeira de Mello Monteiro
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-18       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.